Low Serum 25-Hydroxyvitamin D Concentrations Are Associated with Increased Risk for Melanoma and Unfavourable Prognosis

Benjamin Bade¹, Alexander Zdebik¹, Stefan Wagenpfeil², Stefan Gräber², Jürgen Geisel³, Thomas Vogt¹, Jörg Reichrath¹*

1. Center for Clinical and Experimental Photo-Dermatology, Department of Dermatology, The Saarland University Hospital, Homburg, Germany, 2. Institute of Medical Biometry, Epidemiology and Medical Informatics, The Saarland University Hospital, Homburg, Germany, 3. Department of Clinical Chemistry and Laboratory Medicine, The Saarland University Hospital, Homburg, Germany

*joerg.reichrath@uks.eu

These authors contributed equally to this work.

Abstract

**Background:** Low vitamin D status (serum 25(OH)D concentration) is associated with increased incidence and unfavourable outcome of various types of cancer. However, there are limited data on influence of serum 25(OH)D on risk and prognosis of malignant melanoma.

**Methods:** Basal serum 25(OH)D concentrations were retrospectively analyzed in a cohort of melanoma patients (n=324) and healthy controls (n=141). We tested the hypothesis that serum 25(OH)D concentrations are predictive of melanoma risk, thickness of primary melanomas, and overall survival (OS).

**Results:** Median serum 25(OH)D concentrations were significantly lower (p=0.004) in melanoma patients (median=13.6 ng/ml) as compared to controls (median=15.6 ng/ml). Primary tumors of patients with low serum 25(OH)D concentrations (<10 ng/ml) had significantly (p=0.006) greater Breslow thickness (median: 1.9 mm) as compared to patients with higher levels (>20 ng/ml; median: 1.00 mm). Patients with 25(OH)D serum concentrations in the lowest quartile had inferior overall survival (median: 80 months) comparing with the highest quartile (median: 195 months; p=0.049).

**Conclusions:** Our data support the concept that serum 25(OH)D concentrations are associated with risk and prognosis of melanoma. Whether normalizing serum 25(OH)D concentrations in these patients improves outcomes will require testing in future clinical trials.
Introduction

Over the last 20 years, an increasing body of epidemiological and experimental studies has supported the so called “vitamin D/cancer hypothesis”. The basis of the experimental support was the demonstration of the almost ubiquitous expression of both the vitamin D receptor (VDR) [1, 2] and the activating enzyme (vitamin D-1α-hydroxylase, CYP27B1) [3], which converts serum 25-hydroxyvitamin D₃ (25(OH)D) into the biologically active vitamin D metabolite 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D). Binding and transcriptional activation of VDR by 1,25(OH)₂D regulate multiple cellular functions that are implicated in carcinogenesis and cancer progression, including proliferation, differentiation, apoptosis, angiogenesis and metastatic potential [4–10]. In line with these experimental studies, numerous pro- and retrospective epidemiological studies have now convincingly shown that low serum 25(OH)D concentrations are associated in colorectal cancer and various other types of cancer with a significantly increased risk for the development of the disease [11–16] and a relatively poor prognosis [17–19]. In agreement with these findings, a meta-analysis of five epidemiological studies showed a 51% reduction for the risk of colorectal cancer in people with serum 25(OH)D concentrations in the highest versus the lowest quintiles (p<0.0001) [20]. Additionally, a prospective, randomised, controlled trial (RCT) of vitamin D and calcium supplementation in 1,179 women revealed a 60% reduction in all-cancer risk in the intervention arm (p<0.03) [21]. It has to be noted that the majority of RCTs published so far, analyzing the impact of vitamin D on cancer, showed no significant results. However, most of these studies were limited due to poor study designs, including low doses and/or short duration of the supplementation with vitamin D, or because of low compliance [22, 23].

Meanwhile, it is well accepted that lack of sun exposure leads to vitamin D deficiency, since 90% of all gained vitamin D has to be formed in the skin by UV-B exposure [24–25]. The impact of solar UV-exposure on incidence and prognosis of melanoma is yet not well understood, as is the influence of the cutaneous synthesis of vitamin D [26–27]. On one side, increased risk of melanoma is reported in individuals with a history of recurring intensive, short time UV exposure (most importantly sunburns in childhood), especially in fair-skinned individuals [28–29]. On the other side, moderate sun exposure has been reported to exert a protective effect against and to be associated with a relatively favourable prognosis and increased overall survival rates in melanoma patients [26, 27, 30]. Additionally, some pilot studies have supported the hypothesis that serum 25(OH)D concentrations may be associated with risk and prognosis of melanoma [31, 32]. To gain further insights into the relevance of serum 25(OH)D concentrations on risk and prognosis of melanoma, we have now carried out this retrospective study in 324 German patients and 141 healthy controls.
Methods
This retrospective study was performed in agreement with the Ethical committee of the “Ärztekammer des Saarlandes” (No. 247/12). Patient records/information was anonymized and de-identified prior to analysis. The study population included 324 Patients from the Department of Dermatology of the University of Regensburg with histologically proven primary cutaneous melanomas of different stages. All 324 venous blood samples were taken between January 2000 and December 2004. In 291 melanoma patients, blood samples were taken at the time of primary diagnosis. 33 melanoma patients were diagnosed between 1984 and 1999 (venous blood samples were taken between January 2000 and December 2004 in these patients as well). All blood samples were immediately processed and separated, then aliquoted and stored at $-40^\circ\text{C}$. Basal 25(OH)D serum concentrations (ng/ml; 1 ng/ml $= 2.5$ nmol/L) were analyzed at the Department of Clinical Chemistry and Laboratory Medicine of the Saarland University Hospital in Homburg using LIAISON® 25-OH Vitamin D Total (DiaSorin, Dietzenbach, Germany). The lower detection limit of this assay is at 4 ng/ml, and the within-pair coefficient of variation (CV) of this assay was in a recently published study 4.9% using blinded quality control samples [33].

Clinical data were abstracted from medical records using a standard protocol. The observation time of this retrospective study started at the time of diagnosis, patients were observed until death or December 2004, whichever came first. Venous blood samples from the control group (141 healthy German individuals; 60 men, 81 women; age: mean 55.09, median 54, 14–34 years: n=40, 35–64 years: n=66, >/=65 years: n=35) were collected at the Saarland University Hospital between February 2001 and April 2006, data have been published previously [31].

The study population was divided into different groups of interest (e.g. 25(OH)D levels, tumor thickness, survival, gender, age, time of venipuncture); medians, means and standard deviations were calculated. Because 25(OH)D serum concentrations could not be assumed to be normally distributed (demonstrated by Kolmogorov-Smirnov-Test), differences between individual groups were analysed with the Mann-Whitney U-test, Kruskal-Wallis-test, or with Log-Rank-test in Kaplan-Meier analyses. A p-value of <0.05 was considered statistically significant. Statistical analysis also included multivariate analysis and ANOVA. All statistical analyses were performed using the statistical package SPSS Version 18 (IBM, USA).

Results
Moderately lower serum 25(OH)D concentrations in melanoma patients (diagnosed in wintertime) as compared to controls
Population characteristics is displayed in Table 1. Blood samples of the control group and from melanoma patients were matched by season. For blood samples of the control group were taken from Fall through Spring (Oct-Apr), they were
Table 1. Please note lower serum 25(OH)D concentrations in melanoma patients (diagnosed in wintertime) as compared to controls, and in metastasized as compared to non-metastasized patients.

| Variable                  | Melanoma patients (n=324) | Control (n=141) | Total (n=465) |
|---------------------------|---------------------------|-----------------|--------------|
| Gender                    |                           |                 |              |
| Men                       | 174                       | 60              | 234          |
| Women                     | 150                       | 81              | 231          |
| Age                       |                           |                 |              |
| Mean                      | 56.3                      | 55.1            |              |
| Median                    | 60.0                      | 54.0            |              |
| <51                       | 105                       | 84              | 189          |
| Serum 25(OH)D median      | 18.5 ng/ml                | 13.85 ng/ml     |              |
| 52–66                     | 108                       | 27              | 135          |
| Serum 25(OH)D median      | 16.4 ng/ml                | 18.4 ng/ml      |              |
| >67                       | 111                       | 30              | 141          |
| Serum 25(OH)D median      | 14.2 ng/ml                | 16.25 ng/ml     |              |
| p=0.003                   |                           | p=0.38          |              |
| Serum 25(OH)D (ng/ml)     |                           |                 |              |
| n                         | 324                       | 141             | 465          |
| Mean                      | 18                        | 18.77           | 18.23        |
| Median                    | 16.2                      | 15.6            | 15.7         |
| SD                        | 10.59                     | 11.11           | 10.74        |
| Interquartile range       | 14.5 ng/ml                | 17.2 ng/ml      | 14.3 ng/ml   |
| Serum 25(OH)D (grouping) |                           |                 |              |
| <20 ng/ml                 | 207 (63.89%)              | 89 (63.1%)      | 296 (63.7%)  |
| <10 ng/ml                 | 82 (39.6%)                | 39 (43.8%)      | 121 (40.9%)  |
| 10–20 ng/ml               | 125 (60.4%)               | 50 (56.2%)      | 175 (59.1%)  |
| >20 ng/ml                 | 117 (36.11%)              | 52 (36.9%)      | 169 (36.3%)  |

Vitamin D status in melanoma patients vs. Controls (venipunctured in winter)

|                      | all MMs | Control |
|----------------------|---------|---------|
| n                    | 127     | 141     |
| Mean                 | 15.1    | 18.8    |
| Median               | 13.6    | 15.6    |
| SD                   | 10.1    | 11.1    |
| p=0.004              |         |         |

Serum 25(OH)D levels (ng/ml) in metastasized and non-metastasized melanoma patients

|                      | metastasized | non-metastasized |
|----------------------|--------------|------------------|
| n                    | 55           | 269              |
| Mean                 | 16.63        | 18.29            |
| Median               | 15.3         | 16.2             |
| SD                   | 10.67        | 10.57            |
| p=0.29               |              |                  |

In the cohort of all melanoma patients significant (p=0.003) age-related differences in serum 25(OH)D concentrations were observed (20–51 yrs.: median=18.5 ng/ml, n=105; 52–66 yrs.: median=16.4 ng/ml, n=108; >67 yrs.: median=14.2 ng/ml, n=111).
compared with a cohort of melanoma patients where blood was taken in the same period (Oct-Apr). In both study groups, about 63% of the population had a deficient vitamin D status (serum 25(OH)D levels <20 ng/ml). Median serum 25(OH)D concentrations were significantly lower (p=0.004) in melanoma patients (median=13.6 ng/ml; n=127) as compared to controls (median=15.6 ng/ml; n=141) (Table 1). Additional statistical tests, including age and time of blood draw (BMI data were not available) in multiple analyses and ANOVA, confirmed our results. Considering 25(OH)D as dependent and sex, age, season of blood draw as well as group as independent variables, the adjusted group effect resulted in a p-value of 0.012 (Table 2).

Serum 25(OH)D concentrations are associated with thickness of primary melanomas

Patients with serum 25(OH)D concentrations <20 ng/ml (n=199; median=1.53 mm) had significantly (p=0.002) thicker primary melanomas than patients with concentrations >20 ng/ml (n=108; median=1.00 mm) (Fig. 1a). Furthermore, we here report for the first time evidence of an inverse J-shaped curve (p=0.033), indicating that high serum 25(OH)D concentrations (>40 ng/ml; n=12; median=1.155 mm) maybe associated with thicker primary melanomas as well (Fig. 1b). Additional statistical tests, including gender and time of blood draw in multiple analyses, confirmed our finding that serum 25(OH)D concentrations are associated with Breslow thickness of primary melanomas (n=307, p-value=0.013) (Table 3).

In contrast to serum 25(OH)D concentration, Breslow thickness of primary melanomas is not associated with season

We found significant (p=0.000) variations in serum 25(OH)D concentrations throughout the seasons in melanoma patients (n=324), with a peak in autumn (Aug–Oct) (median=21.3 ng/ml) and a low in springtime (Feb–Apr) (median=10.15 ng/ml) (Fig. 2a). An association of Breslow thickness and season was not observed (p=0.543) (Fig. 2b).

Age is associated with serum 25(OH)D concentrations and with Breslow thickness of primary melanomas

In the cohort of all melanoma patients significant (p=0.003) age-related differences in serum 25(OH)D concentrations were observed (20–51 yrs.: median=18.5 ng/ml, n=105; 52–66 yrs.: median=16.4 ng/ml, n=108; >67 yrs.: median=14.2 ng/ml, n=111) (Table 1). Additionally, we found (p=0.07) age-related differences in Breslow thickness of primary melanomas (20–51 yrs: median=1.1 mm; 52–66 yrs.: median=1.2 mm; >67 yrs.: median=1.8 mm).
Serum 25(OH)D concentrations are associated with survival of melanoma patients

When dividing the cohort of melanoma patients according to their serum 25(OH)D concentrations into quartiles, a significant difference in survival between the 1st (lowest serum 25(OH)D concentrations; 4–9.86 ng/ml) and 4th (highest serum 25(OH)D concentrations; 24.4–59.6 ng/ml) quartiles was found (p=0.049). Kaplan-Meier analysis showed a median overall survival of melanoma patients in the 1st quartile (n=81) of 80 months, while in contrast patients in the 4th quartile (n=81) had a median overall survival of 195 months (Fig. 3a). Age at time of venipuncture has no significant influence on OS (p=0.2). Tumor stage has a significant influence on OS with p-values, 10^-3 and 0.002 for tumor stages 4 and 3, respectively. This finding may be due to a dependence of tumor stage on 25(OH)D level.

Season of venipuncture is not associated with survival in melanoma patients

Comparing the time of survival of melanoma patients venipunctured in winter (Nov-Jan) (n=57) and summer (May-Jul) (n=92) with each other, no significant difference was observed. The median survival in the winter cohort was 62 months as compared to 57 months in the summer cohort (n=149; p=0.056) (Fig. 3b).

Gender is associated with survival in melanoma patients

The female gender (n=130) had a significant longer overall survival compared to the male gender (n=145). In mean, the males survived 71 months in comparison to the females that survived 82 months (p=0.003) (Fig. 3c).

Discussion

Even though there is still no agreement of a threshold concentration of serum 25(OH)D for vitamin D deficiency, many experts in the field define it by serum...
concentrations of 25(OH)D <20 ng/ml [25]. According to this definition, we here report a high prevalence of vitamin D deficiency both in melanoma patients (63%) and in healthy controls (63%) in the German population. Our results are in agreement with other reports published in the literature, reporting a high prevalence of vitamin D deficiency in Germany [34]. Interestingly, median serum 25(OH)D concentrations were moderately but significantly lower (p=0.004) in melanoma patients (13.6 ng/ml; n=127) as compared to controls (15.6 ng/ml; n=141). However, this complex topic requires careful consideration of multiple
Table 3. Multiple analyses confirm the association of serum 25(OH)D concentration with Breslow thickness of primary melanomas.

| Independent variables                  | Regression coefficient | p-value |
|----------------------------------------|------------------------|---------|
| Gender                                 | 0.23                   | 0.31    |
| Season of blood draw                   | -0.04                  | 0.86    |
| serum 25(OH)D concentration           | -0.026                 | 0.013   |

Additional statistical tests, including gender and time of blood draw in multiple analyses, confirmed our finding that serum 25(OH)D concentrations are associated with Breslow thickness of primary melanomas (n=307; 17 Patients were excluded from this cohort due to missing clinical data). Considering Breslow thickness of primary melanomas as dependent and gender, season of blood draw as well as serum 25(OH)D concentration as independent variables, the adjusted serum 25(OH)D concentration effect resulted in a p-value of 0.013.

doi:10.1371/journal.pone.0112863.t003

Figure 2. 25(OH)D concentration, age, season and Breslow thickness of primary melanomas. We found significant (p<0.001) variations in serum 25(OH)D concentrations throughout the seasons in melanoma patients (n=324), with a peak in autumn (Aug-Oct) (median=21.3 ng/ml) and a low in springtime (Feb-Apr) (median=10.15 ng/ml) (2a). An association of Breslow thickness and season was not observed (p=0.543, n=307), 17 patients from the cohort were excluded due to missing clinical data (2b). Additionally, we found (p=0.07) age-related differences in Breslow thickness of primary melanomas (20–51 yrs.: median=1.1 mm; 52–66 yrs.: median=1.2 mm; >67 yrs.: median=1.8 mm) (2c). Boxes represent the values (median) within the 25th and 75th percentiles.

doi:10.1371/journal.pone.0112863.g002
factors simultaneously. Therefore, we performed additional statistical tests, including age and time of blood draw in multiple analyses and ANOVA, that confirmed our results. Considering 25(OH)D as dependent and sex, age, season of blood draw as well as group as independent variables, the adjusted group effect resulted in a p-value of 0.012. It has to be noted that, although the difference between median concentrations of 13.6 in melanoma patients versus 15.6 in controls is statistically significant, it may be of limited physiologic significance. Moreover, this small difference is within the error of the assay.

Figure 3. Serum 25(OH)D concentrations are associated with survival of melanoma patients. When dividing the cohort of melanoma patients according to their serum 25(OH)D concentrations into quartiles, a significant difference in survival from time of diagnosis between the 1st (lowest serum 25(OH)D concentrations; 4–9.86 ng/ml) and 4th (highest serum 25(OH)D concentrations; 24.4–59.6 ng/ml) quartiles is found (p=0.049). Kaplan-Meier analysis shows a median OS of melanoma patients in the 1st quartile (n=81) of 80 months, while in contrast patients in the 4th quartile (n=81) have a median OS of 195 months. Age at time of venipuncture has no significant influence on OS (p=0.2). Tumor stage has a significant influence on OS with p-values<10^{-3} and 0.002 for tumor stages 4 and 3, respectively. This finding may be due to a dependence of tumor stage on 25(OH)D level (3a). Comparing the survival of melanoma patients venipunctured in winter (Nov-Jan) (n=57) and summer (May-Jul) (n=92) with each other, no significant difference is observed. The median survival in the winter cohort is 62 months as compared to 57 months in the summer cohort (n=149; p=0.056) (3b). The female gender (195 month, n=150) has a significant longer OS compared to the male gender (141 month, n=174) (p=0.003) (3c).
Sun avoidance after a diagnosis of malignant melanoma is a common phenomenon, and our present study adds to the growing body of evidence that melanoma patients have suboptimal concentrations of serum 25(OH)D [32]. In a small pilot study, we had failed previously to show lower levels of 25(OH)D in melanoma patients as compared to healthy individuals [35], however these results are likely due to the fact that we analyzed in that study only patients with relatively thin melanomas. Our present study is in agreement with our later follow up study [31], indicating that serum concentrations of 25(OH)D are moderately lower in German melanoma patients as compared to controls. A study reported in 1992 a 5% lower level of 1,25-dihydroxyvitamin D in 23 healthy donors who later went on to develop a melanoma, although this was a non-significant effect [36]. Moreover, we reported previously, that stage IV melanoma patients (metastasized disease) have lower serum concentrations of 25(OH)D as compared to non-metastasized melanoma patients [31]. In our present study, the metastasized melanoma patients collective also showed slightly lower serum concentrations of 25(OH)D as compared to non-metastasized melanoma patients, although these differences were not statistically significant. However, it has to be noted that these findings should be interpreted with care: they represent associations that do not have to be causative for the pathogenesis or progression of melanoma. The possibility must be considered that serum concentrations of 25(OH)D represent a marker for another unknown causal relationship.

Interestingly, we found an association of serum 25(OH)D concentrations, measured at the time of diagnosis, with Breslow thickness of primary melanomas. Vitamin D deficient patients had significantly thicker primary melanomas as compared to patients with a sufficient vitamin D status. These results in German patients are well in line with findings of a prospective cohort study reported in 2009 in another population, showing that melanoma patients with relatively low levels of 25(OH)D have a relatively higher Breslow thickness of their primary melanomas [32]. Moreover, we here report for the first time evidence of an inverse J-shaped curve, indicating that high serum 25(OH)D concentrations (>40 ng/mL) maybe associated with thicker primary melanomas as well. However, it has to be noted that additional clinical data that would be helpful and informative to know were not available for our twelve melanoma patients who had blood levels of 25(OH)D >40 ng/mL. It is generally accepted that it is very difficult to attain a blood level above 40 ng/mL unless a person is exposed to sunlight on a frequent basis and only in the spring and summer and fall. When looking at variations in serum 25(OH)D concentrations throughout the seasons in our melanoma patients (Fig. 2a) it appears that most of the patients were vitamin D deficient but that at each of the seasons several had 25(OH)D blood levels above 40 ng/mL whether it be at the end of the winter or at the end of the summer. This maybe of importance for the interpretation of the so-called inverse J-shaped curve. It may well be that at least some of these individuals were vitamin D deficient and being treated for vitamin D deficiency by their physician. Thus, it can be speculated that these individuals were at a higher risk for having a more aggressive melanoma because of they have been vitamin D deficient; and that only
because they were being treated for their vitamin D deficiency at the time of
venipuncture their blood level was above 40 ng/mL. According to some studies,
the present optimal serum 25(OH)D concentration is approximately 16–24 ng/ml
\[22,37–39\]. However, there is a need for larger, more comprehensive clinical
and epidemiological studies \[40\]. Variations in circulating 25(OH)D concentrations
are suggested to be a significantly heritable trait, based on a recent analysis of 1762
elderly men and women in community-based health care \[41\]. In 2010, common
genetic determinants of vitamin D insufficiency have been identified in a genome-
wide association study \[42\]. In that investigation, variants at three loci reached
geno?me-wide significance in discovery cohorts for association with 25-
hydroxyvitamin D concentrations, and were confirmed in replication cohorts:
4p12 (overall \(p=1.9 \times 10(−109)\) for rs2282679, in GC); 11q12 (\(p=2.1 \times 10(−27)\)
for rs12785878, near DHCR7); and 11p15 (\(p=3.3 \times 10(−20)\) for rs10741657, near
CYP2R1) \[42\]. Participants with a genotype score (combining the three
confirmed variants) in the highest quartile were at increased risk of having 25-
hydroxyvitamin D concentrations lower than 75 nmol/L (OR 2.47, 95% CI 2.20–
2.78, \(p=2.3 \times 10(−48)\)) or lower than 50 nmol/L (1.92, 1.70–2.16,
\(p=1.0 \times 10(−26)\)) compared with those in the lowest quartile \[42\]. It has been
concluded that variants near genes involved in cholesterol synthesis, hydroxyla-
tion, and vitamin D transport affect vitamin D status and that genetic variation at
these loci identifies individuals who have substantially raised risk of vitamin D
insufficiency \[42\].

It is obvious that there has been adaptation to UV-B irradiation such as the skin
color, therefore there might be population differences in the optimal 25(OH)D
serum concentration. This indicates that additional studies of optimal 25(OH)D
serum concentrations for disease prevention are necessary comparing different
populations and groups of a population. After those studies, it will be possible to
determine what the optimal serum concentration of 25(OH)D for prevention of
melanoma and other diseases is.

An important result of this study is the finding, that there is a significant
survival benefit (\(p=0.049\)) for patients with higher serum 25(OH)D concentra-
tions (fourth quartile: median survival=195 months) compared to patients with
lower levels (first quartile: median survival=80 months). In a prospective cohort
study reported in 2009, higher serum concentrations of 25(OH)D were associated
in melanoma patients with lower Breslow thickness at diagnosis and were
independently protective of relapse and death \[32\].

Looking at seasonal variations, we were able to observe significant changes in
25(OH)D levels throughout the year (\(p=0.000\) with expected highest levels in
autumn (Aug-Oct) (median=21.3 ng/ml) like an earlier study showed before \[32\]
and lowest in spring (median=10.15 ng/ml). The winter results are unexpectedly
high due to a peak-increase in January which we cannot explain. Opposite to
vitamin 25(OH)D, tumor thickness is indifferent throughout the seasons
(\(p=0.543\)), so they seem to have no influence. In our present study, we were
unable to show an association of season with overall survival of melanoma
patients, as reported by others for other types of cancer \[43\]: our patients
venipunctured in summer (May-Jul) had no significant benefit in overall survival than the ones venipunctured in winter (Nov-Jan).

In our present study, the serum 25(OH)D concentrations in melanoma patients differ statistically significant depending on age. We here report that younger melanoma patients have higher serum 25(OH)D concentrations than older patients. These findings are opposite to results of a previous study in the British population [32] which stated that younger individuals have lower serum 25(OH)D concentrations than older ones. There is typically an increase in overall body fat with ageing, creating a larger distribution volume for the fat-soluble 25(OH)D, and the potential for characterizing patients as vitamin D deficient [44]. Moreover, the capacity of the skin to produce vitamin D decreases with age. Interestingly, younger melanoma patients had thinner primary tumors at time of diagnosis than older patients. These findings are well in line with recent results of a study in the British population [32]. It can be speculated whether the relatively higher vitamin D serum concentrations in the younger population cause this association.

In summary, results of this retrospective study strongly support the hypothesis that the vitamin D status predicts risk and prognosis of melanoma and that melanoma patients have a suboptimal vitamin D status. However, one has to keep in mind that we only report associations, and that a causal relationship has to be confirmed in future studies. Other limitations of our work include the study design (retrospective analyses) and the techniques used (no confirmation of 25(OH)D measurements by mass spectroscopy). Whether normalizing serum 25(OH)D concentrations in these patients improves outcomes will require testing in future clinical trials. Further studies are urgently needed to investigate the role of the vitamin D endocrine system in melanoma.

Author Contributions

Conceived and designed the experiments: JR BB. Performed the experiments: BB. Analyzed the data: BB AZ SW. Contributed reagents/materials/analysis tools: CH JR BB SG JG TV. Wrote the paper: BB JR AZ SW.

References

1. Meggouh F, Lointier P, Saez S (1991) Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res 51(4): 1227–33.
2. Vandewalle B, Adenis A, Hornez L, Revillion F, Lefebvre J (1994) 1,25-dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. Cancer Lett 1994 86(1): 67–73.
3. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, et al. (2001) Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86(2): 888–94.
4. Vandewalle B, Wattez N, Lefebvre J (1995) Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 97(1): 99–106.
5. Diaz GD, Parasekva C, Thomas MG, Binderup L, Hague A (2000) Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60(8): 2304–12.

6. Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C, Brasitus TA, et al. (2000) A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Wa1, and p27Kip1. Endocrinology 141(11): 3931–9.

7. Iseki K, Tatsuta M, Uehara H, Ishii H, Yano H, et al. (1999) Inhibition of angiogenesis as a mechanism for inhibition by 1alpha,25-dihydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999; 81(5): 730–3.

8. Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, et al. (2005) 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 2005; 24(43): 6533–44.

9. Lamprecht SA, Lipkin M (2001) Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci 2001; 952: 73–87.

10. Evans SR, Shchepotin EI, Young H, Rochon J, Uskokovic M, et al. (2000) 1,25-Dihydroxyvitamin D3 synthetic analogs inhibit spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. Int J Oncol 16: 1249–1254.

11. Garland CF, Comstock GW, Garland FC, Helsinger KJ, Shaw E, et al. (1995) Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176–1178.

12. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Colon cancer and serum vitamin D metabolite levels 10–17 years prior to diagnosis. Am J Epidemiol 142: 608–611.

13. Tangrea J, Helzlsouer K, Pietinen P, Taylor P, Hollis B, et al. (1997) Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 8: 615–625.

14. Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, et al. (2004) Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 13: 1502–1508.

15. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, et al. (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354: 684–696.

16. Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, et al. (2007) A nested case-control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 99: 1120–1129.

17. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, et al. (2007) Giovannucci E, Su L and Christiani DC: Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small cell lung cancer patients. J Clin Oncol 25(34): 479–485.

18. Goodwin PJ, Ennis M, Pritchard KL, Koo J, Hood N (2008) Frequency of vitamin D (Vit. D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, NO-1, M0 BC. J Clin Oncol 26: (May 20 suppl; abstr 511).

19. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, et al. (2008) Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 26(18): 2937–2939.

20. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, et al. (2007) Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 32: 210–216.

21. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP, et al. (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586–1591.

22. International Agency for Research on Cancer (2008) Vitamin D and Cancer. World Health Organization (WHO) Press, IARC Working Group Report Volume 5, 2008

23. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, et al. (2012) RECORD Trial Group. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). J Clin Endocrinol Metab 97(2): 614–22.

24. Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin Nutr 69: 842–856.

25. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–282.
26. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, et al. (2005) Sun exposure and mortality from melanoma. J Natl Cancer Inst 97(3): 195–199.

27. Berwick M, Lachiewicz A, Pestak C, Thomas N (2008) Solar UV exposure and mortality from skin tumors. Adv Exp Med Biol 624: 117–124.

28. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, et al. (2005) Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41(1): 45–60.

29. Nelemans PJ, Groenendal H, Kienemey LA, Rampen FH, Ruiter DJ, et al. (1993) Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 101(3): 252–255.

30. Rosso S, Sera F, Segnan N, Zanetti R (2008) Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: results from a long-term follow-up study of Italian patients. Eur J Can 44(9): 1275–1281.

31. Nürnberg B, Gräber S, Gärtnert B, Geisel J, Pföhler C, et al. (2009) Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 29(9): 3669–74.

32. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, et al. (2009) Serum 25-hydroxyvitamin D levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 27(2): 5439–44.

33. Meng JE, Hovey KM, Wactawski-Wende J, Andrews CA, Lamonte MJ, et al. (2012) Intraindividual Variation in Plasma 25-Hydroxyvitamin D Measures 5 Years Apart among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev 21(6): 916–24.

34.Hintzpeter B, Mensink GBM, Thierfelder W, Müller MJ, Scheidt-Nave C (2008) Vitamin D status and health correlates among German adults. Eur J Clin Nutr 62(9): 1079–1089.

35. Reichrath J, Querings K (2004) No evidence for reduced 25-hydroxyvitamin D serum levels in melanoma patients. Cancer Causes Control 15: 97–98.

36. Cornwell ML, Comstock GW, Holick MF, Bush TL (1992) Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. Photodermatol Photoimmunol Photomed 9(3): 109–12.

37. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, et al. (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108(1): 104–8.

38. Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, et al. (2007) Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev 16(12): 2784–6.

39. Tuohimaa P, Keisala T, Minasyan A, Cachat J, Kalueff A (2009) Vitamin D, nervous system and aging. Psychoneuroendocrinology (Suppl 1): 278–286.

40. Mimouni FB, Shamir R (2009) Vitamin D requirements in the first year of life. Curr Opin Clin Nutr Metab Care 12(3): 287–92.

41. Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, et al. (2009) Genetic and non-genetic correlates of vitamins K and D. Eur J Clin Nutr. 63(4): 458–64.

42. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376(9736): 180–8.

43. Holmberg L, Adolfsson J, Mucci L, Garmo H, Adami HO, et al. (2009) Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control 20(5): 663–70.

44. Konradsen S, Ag H, Lindberg F, Hexberg S, Jorde R (2008) Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr 47(2): 87–91.